 United States Food and Drug Administration
"United States Food and Drug Administration" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.
| Descriptor ID |
D014486
|
| MeSH Number(s) |
I01.409.418.750.600.650.760 N03.540.348.500.500.600.650.760
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "United States Food and Drug Administration".
Below are MeSH descriptors whose meaning is more specific than "United States Food and Drug Administration".
This graph shows the total number of publications written about "United States Food and Drug Administration" by people in this website by year, and whether "United States Food and Drug Administration" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 0 | 2 | 2 | | 2000 | 0 | 3 | 3 | | 2001 | 0 | 3 | 3 | | 2002 | 0 | 2 | 2 | | 2003 | 2 | 0 | 2 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 3 | 2 | 5 | | 2007 | 1 | 6 | 7 | | 2008 | 3 | 2 | 5 | | 2009 | 5 | 5 | 10 | | 2010 | 0 | 2 | 2 | | 2011 | 2 | 1 | 3 | | 2012 | 2 | 15 | 17 | | 2013 | 2 | 4 | 6 | | 2014 | 1 | 5 | 6 | | 2015 | 2 | 15 | 17 | | 2016 | 0 | 7 | 7 | | 2017 | 1 | 8 | 9 | | 2018 | 1 | 6 | 7 | | 2019 | 1 | 8 | 9 | | 2020 | 0 | 7 | 7 | | 2021 | 0 | 10 | 10 | | 2022 | 0 | 8 | 8 | | 2023 | 0 | 3 | 3 | | 2024 | 1 | 8 | 9 | | 2025 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "United States Food and Drug Administration" by people in Profiles.
-
Elder C, Pellinen J, Terman SW. The Epilepsy Drug Pipeline: Update on Near-to-Market Therapies. Semin Neurol. 2025 Apr; 45(2):287-297.
-
Pearson AD, Mueller S, Filbin MG, Grill J, Hawkins C, Jones C, Donoghue M, Drezner N, Weiner S, Russo M, Dun MD, Allen JE, Alonso M, Benaim E, Buenger V, de Rojas T, Desserich K, Fox E, Friend J, Glade Bender J, Hargrave D, Jensen M, Kholmanskikh O, Kieran MW, Knoderer H, Koschmann C, Lesa G, Ligas F, Lipsman N, Ludwinski D, Marshall L, McDonough J, McNicholl AG, Mirsky D, Monje M, Nysom K, Pappo A, Rosenfield A, Scobie N, Slaughter J, Smith M, Souweidane M, Straathof K, Ward L, Weigel B, Zamoryakhin D, Karres D, Vassal G. Paediatric strategy forum for medicinal product development in diffuse midline gliomas in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Eur J Cancer. 2025 Feb 25; 217:115230.
-
Dantzer JA, Shaker MS, Greenhawt M. Evolving Food Allergy Clinical Trials to Become More Patient-Centered. J Allergy Clin Immunol Pract. 2025 Apr; 13(4):763-772.
-
Kao DP, Martin JL, Aquilante CL, Shalowitz EL, Leyba K, Kudron E, Reusch JEB, Regensteiner JG. Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration. BMJ Open Diabetes Res Care. 2024 Dec 05; 12(6).
-
Kim-McManus O, Gleeson JG, Mignon L, Smith Fine A, Yan W, Nolen N, Demarest S, Berry-Kravis E, Finkel R, Leonard S, Finlayson S, Augustine E, Lyon GJ, Schule R, Yu T. A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases. Nat Commun. 2024 11 12; 15(1):9802.
-
Walsh C. Genetic Implications for Cancer Management: The Changing Landscape of Poly (ADP-ribose) Polymerase Inhibitor Indications in the Treatment of Ovarian Cancer. Clin Obstet Gynecol. 2024 Dec 01; 67(4):711-719.
-
Xiao M, Molina KC, Aggarwal NR, Beaty LE, Bennett TD, Carlson NE, Fish LE, Hamer MK, Kwan BM, Mayer DA, Peers JL, Wynia MK, Ginde AA. A Machine Learning Method for Allocating Scarce COVID-19 Monoclonal Antibodies. JAMA Health Forum. 2024 Sep 06; 5(9):e242884.
-
Costa E, Girotti S, Mathieu C, Castellani C, Ross JS, Taylor-Cousar JL, Leufkens HGM. Differential times of submission and approval of CFTR modulators for the treatment of Cystic Fibrosis in the United States and the European Union. J Cyst Fibros. 2025 Jan; 24(1):125-132.
-
Blumer V, Januzzi JL, Lindenfeld J, Solomon SD, Psotka MA, Carson PE, Bristow MR, Abraham WT, Gandotra C, Saville BR, O'Connor C, Fiuzat M. Heart?Failure Drug Development Over?the?Eras: From the Heart?Failure Collaboratory. JACC Heart Fail. 2024 Nov; 12(11):1803-1813.
-
Bhat S, Click B, Regueiro M. Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies. Inflamm Bowel Dis. 2024 05 02; 30(5):829-843.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|